Sanofi-Aventis

In 2000 the foundation was renamed the Aventis Foundation subsequent to the 1999 merger of Hoechst and Rhône-Poulenc. Cunningham was subsequently replaced on CBS by Hubie Brown. The Aventis Prizes are managed by the Royal Society, the UK national academy of science, and the Aventis Foundation, a German charitable trust established in 1996 as the Hoechst Foundation with an endowment of €50 million. Cunningham would leave CBS Sports the following season to join the Miami Heat expansion franchise as a minority owner; Cunningham ultimately sold his interest of the Heat on August 12, 1994. The Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, have grown to be one of the world's most prestigious non-fiction literary prizes. In 1987, Cunningham replaced Tom Heinsohn as the lead color commentator (alongside play-by-play man Dick Stockton) for CBS' NBA telecasts. Research and development investment was €4 bn. Cunningham also played on the 1967 Sixers championship team (featuring Wilt Chamberlain, Hal Greer, Chet Walker).

It has operations in more than 100 countries throughout the 5 continents and has 99,700 employees worlwide. Cunningham is well-known for coaching the Philadelphia 76ers to the 1983 NBA Championship. In 2003, Sanofi-Aventis's consolidated sales was €25 bn. William John "Billy" Cunningham (born June 3, 1943 in Brooklyn, New York) is a former pro basketball player and coach, who was nicknamed the "Kangaroo Kid", and coach. Dehecq has been the General Manager of Sanofi since its creation in 1973. One of 50 Greatest Players in NBA History (1996). The merged company was based in Strasbourg, France. Four-time All-Star.

merged with Hoechst Marion Roussel, in turn formed merging Hoechst AG with Roussel and Marion Merrell Dow. All-NBA Second Team (1972). Aventis was formed in 1999 when Rhône-Poulenc S.A. All-NBA First Team (1969, 1970, 1971). The merged company was based in Paris, France. Elected to Naismith Memorial Basketball Hall of Fame (1986). Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo.

French government, desiring a local merger solution, put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running. Government intervention also played an active role. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. Initially, Aventis rejected the bid because it offered inferior value based on the company's share value.

In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn against Aventis. Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo merged with Aventis. . Sanofi-Aventis covers 7 therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

Sanofi-Aventis engages in the research, development, manufacture and marketing of pharmaceutical products for sale principlally in the presciption market. Sanofi-Aventis (Euronext:FR0000120578) (NYSE:SNY), headquartered in Paris, France, is the world's number 3 company in the pharmaceutical industry (behind Pfizer and GlaxoSmithKline, but above Merck and AstraZeneca). Yahoo! - Sanofi-Aventis Company Profile. Sales by geographic area breakdown: 58% from Europe, 24% from US, 18% from rest of the world.

Sales by activity breakdown: 39% from Cardiovascular/Thrombosis, 29% from Central Nervous System, 18% from Internal Medicine, 11% from Oncology, 3% from other pharmaceutical products. Voting right distribution: 21.37% to Total, 17.12% to L'Oréal, 1.54% to employees, and 59.97% to the public. Breakdown of share ownership: 12.65% by Total SA, 10.13% by L'Oréal, 5.47% treasury shares, 1.29% employees, the remaining 70.46% are publicly traded. Gérard Le Fur, Senior EVP.

Jean-François Dehecq, Chairman and CEO.